Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Chemical/toxin · Other
- Reported indication
- Symptomatic cognitive impairment/dementia (EGb761 marketed/registered as a herbal medicinal product in Germany and some EU/Asian markets; not an FDA-approved drug)
- First approval
- Not recorded
- Development stage
- Regionally marketed herbal for dementia/cognition; acute post-stroke recovery use unproven/ongoing
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- B1260; Common ginkgo leaf; EGB 761; EGB-761; Ginkgo; Ginkgo biloba; Ginkgo biloba, ext.; Ginkgo biloba extract; Ginkgo biloba leaf; Ginkgo biloba leaf dry extract; Ginkgo folium; Ginkgo leaf; Tanakan; Tebonin forte; Yinxingye
- Note
- Not recorded
Clinical trials 7
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Pragmatic Open-label, Parallel-group Clinical Trial on the Effectiveness of Extract of Ginkgo Biloba Leaves Tablets as add-on to Standard of Care in Participants With Cognitive Impairment After an Acute Ischemic Stroke (GiCIIS)
Ischemic Stroke Hospitalized · Impairment, Cognitive
Enrolment: 400 · Results not recorded
The Influence of Concurrent Administration of Echinacea Purpurea, Ginkgo Biloba, or Panax Ginseng on the Steady State Pharmacokinetic Profile of Lopinavir/Ritonavir in Healthy Volunteers
Healthy
Enrolment: 47 · Results not recorded
Effect of EGb 761 on the Ratio of the Isoforms of the Protein Precursor of Beta Amyloid Platelets on Patients With Mild to Moderate Alzheimer's Disease. A Phase II, Randomised, Double-blind Trial, on Parallel Groups Versus Placebo.
Alzheimer Disease
Enrolment: 40 · Results not recorded
Is Cerebonin (Egb761) a Disease-modifying Therapy in Mild Cognitive Impairment
Alzheimer Disease (AD) · Mild Cognitive Impairment (MCI)
Enrolment: 50 · Results not recorded
Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity
Blood Pressure · Cognition
Enrolment: 48 · Results not recorded
Clinical Trial to Assessment the PK/PD Characteristics and Safety After co-Administration of Cilostazol With Ginkgo Biloba or Placebo in Healthy Subject.
Healthy
Enrolment: 40 · Results not recorded
Glucosamine Sulphate and Ginkgo Biloba for Treating Tinea Pedis
Foot Infection Tinea Pedis
Enrolment: 30 · Results not recorded
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
RatChemical/toxinReported as "Wistar Sprague"; MeSH indexing lists Rats, WistarMalen = 30 rats in total, 10 per group across three groupsCo-administered with doxorubicin
Model: Acute doxorubicin induced cardiotoxicity, doxorubicin 20 mg/kg
Doxorubicin raised cardiac troponin I, brain natriuretic peptide, caspase-3, lipid peroxidase, malondialdehyde and tumour necrosis factor alpha and lowered glutathione compared with controls (p<0.01). Co-administration of Ginkgo biloba significantly reduced cardiac troponin I and caspase-3 and rais…
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
RatOtherSprague-DawleyMaleSystemic administration, specific route not stated
Model: Chronic constriction injury (CCI) of the sciatic nerve
Systemic EGb761 inhibited neuropathic pain behaviour, reduced H2O2-induced depolarisation of DRG neurons and lowered p-JNK expression in DRG.
Extraction: extract · Supplied extraction confidence: 0.45. Machine-extracted fields require source verification.
